Mechanistic study of the inhibition of monoamine oxidase-B by quercetin as the potential therapeutic strategy for Parkinson’s Disease: An in silico approach

Baul, Himadri Shekhaar; Muniyan, Rajiniraja

doi:10.3233/jcm-180854

Cited by 5 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These flavonoids were reported to have an impact on gamma-aminobutyric acid (GABA) receptors producing sedation, anxiolytic, or anticonvulsive effects [ 41 ] . Also, quercetin can inhibit monoamine oxidase (MAO), which involved in mood disorder, depression, and oxidative stress [ 42 , 43 ]. This can be supported by the recent animal study, which reported that 14 days of ingestion of quercetin (20 mg/kg) could reverse stress-induced anxiety and depression in mice [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, and placebo-controlled trial

Lau

Shahar

Mohamad

et al. 2020

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Persicaria minor extract exhibits antioxidant and anti-inflammatory properties and has potential effects on cognitive function and mood. However, the effects of P.minor on brain activation and biomarkers have not been studied among older adults. This multicentre, randomized, double-blinded, placebo-controlled study aimed to investigate the effect of 6 months P.minor extract supplement (Biokesum®) on cognition, mood, biomarkers, and brain activation among older adults with Mild Cognitive Impairment (MCI). Method A total of 36 Malaysian community-dwelling older adults with MCI (60–75-year-old) were randomized into Biokesum® (n = 18) and placebo group (n = 18). Each subject consumed one capsule of Biokesum® (250 mg/capsule) or placebo (maltodextrin, 280 mg/capsule) twice daily for 6 months. Cognitive function and mood were assessed at baseline, 3rd, and 6th-month using neuropsychological tests (MMSE, Digit Span, RAVLT, Digit Symbol, and Visual Reproduction) and Profile of Mood State (POMS) questionnaire. Blood lipid profile, fasting blood glucose, and biomarkers (MDA, LPO, COX-2, iNOS, and BDNF) were measured at baseline and 6th month. By the end of the intervention, there were 30 compliers (Biokesum®: N = 15; Placebo: N = 15) and 6 dropouts. For brain activation assessment, 15 subsamples (Biokesum®: N = 8; Placebo: N = 7) completed N-back and Stroop tasks during fMRI scanning at baseline and 6th month. The dorsolateral prefrontal cortex (Brodmann’s area 9 and 46) was identified as a region of interest (ROI) for brain activation analysis using SPM software. Results Two-way mixed ANOVA analysis showed significant improvements in Visual Reproduction II (p = 0.012, partial η2 = 0.470), tension (p = 0.042, partial η2 = 0.147), anger (p = 0.010, partial η2 = 0.207), confusion (p = 0.041, partial η2 = 0.148), total negative subscales (p = 0.043, partial η2 = 0.145), BDNF (p = 0.020, partial η2 = 0.179) and triglyceride (p = 0.029, partial η2 = 0.237) following 6 months of Biokesum® supplementation. Preliminary finding also demonstrated significant improvement at 0-back task-induced right DLPFC activation (p = 0.028, partial η2 = 0.652) among subsamples in Biokesum® group. No adverse events were reported at the end of the study. Conclusion Six months Biokesum® supplementation potentially improved visual memory, negative mood, BDNF, and triglyceride levels among older adults with MCI. Significant findings on brain activation at the right DPLFC must be considered as preliminary. Trial registration Retrospectively registered on 30th August 2019 [ISRC TN12417552].

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, and placebo-controlled trial

Lau

Shahar

Mohamad

et al. 2020

BMC Complement Med Ther

View full text Add to dashboard Cite

show abstract

“…Excitatory cells of the cerebellum that have been treated with H 2 O 2 experience nuclear translation of Nrf2 and increased expression of glutathione when exposed to quercetin ( 120 ). Finally, in silico molecular docking experiments have revealed that the active sites of monoamine oxidase-B stably interact with quercetin, suggesting that quercetin could prevent increased ROS production and oxidative stress associated with the upregulation of monoamine oxidase-B in PD ( 121 ).…”

Section: Senolytic and Senomorphic Secondary Metabolites In ...mentioning

confidence: 99%

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

Miller,

Darji,

Walaieh

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

Drosophila melanogaster is a valuable model organism for a wide range of biological exploration. The well-known advantages of D. melanogaster include its relatively simple biology, the ease with which it is genetically modified, the relatively low financial and time costs associated with their short gestation and life cycles, and the large number of offspring they produce per generation. D. melanogaster has facilitated the discovery of many significant insights into the pathology of Parkinson’s disease (PD) and has served as an excellent preclinical model of PD-related therapeutic discovery. In this review, we provide an overview of the major D. melanogaster models of PD, each of which provide unique insights into PD-relevant pathology and therapeutic targets. These models are discussed in the context of their past, current, and future potential use for studying the utility of secondary metabolites as therapeutic agents in PD. Over the last decade, senolytics have garnered an exponential interest in their ability to mitigate a broad spectrum of diseases, including PD. Therefore, an emphasis is placed on the senolytic and senomorphic properties of secondary metabolites. It is expected that D. melanogaster will continue to be critical in the effort to understand and improve treatment of PD, including their involvement in translational studies focused on secondary metabolites.

show abstract

“…The properties of ADMET pro le include adsorption, digestion, metabolism, excretion, and toxicity which perform major roles in the development and discovery of drugs [120][121][122][123][124][125][126][127][128][129][130][131][132]. The database comprises of 5 quantitative regression models and 22 qualitative classi cations which implement the result with high predictive precision [133][134][135][136][137][138][139][140][141][142][143][144][145]. The appraisal of these properties was carried out using admetSAR (http://lmmd.ecust.edu.cn:8000/).…”

Section: Bioactivity and Admet Pro Ling Of Compoundmentioning

confidence: 99%

Structure-Based Virtual Screening, Molecular Docking, MolecularDynamics Simulation of VEGF Inhibitors for the Clinical Treatment of Ovarian Cancer

Mukherjee

Abdalla

Yadav³

et al. 2021

Preprint

View full text Add to dashboard Cite

VEGF and its receptor play an important role both in physiologic and pathologic angiogenesis, which is identified in ovarian cancer progression and metastasis development. The aim of the present investigation is to identify a potential VEGF inhibitor which is playing a crucial role in stimulating the immunosuppressive microenvironment in tumour cells of ovary and to examine for an effectiveness of identified inhibitor for treatment of ovarian cancer using various In silico approaches. 12 established VEGF inhibitors were collected from various literature. The compound AEE788 displays the great affinity towards the target protein as a result of docking study. AEE78 was further used for structure base virtual screening in order to obtain more structurally similar compound with high affinity. Among the 80 Virtual screened compounds, CID 88265020, explicates much better affinity than established compound AEE788. Based on Molecular Dynamics Simulation, pharmacophore and comparative toxicity analysis of both the best established compound and the best virtual screened compound displayed a trivial variation in associated properties. The virtual screened compound CID 88265020 have the high affinity with the lowest re-rank score, and holds a huge potential to inhibit the VGFR and can be implemented for prospective of future investigations in Ovarian Cancer.

show abstract

Mechanistic study of the inhibition of monoamine oxidase-B by quercetin as the potential therapeutic strategy for Parkinson’s Disease: An in silico approach

Cited by 5 publications

References 14 publications

The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, and placebo-controlled trial

The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, and placebo-controlled trial

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

Structure-Based Virtual Screening, Molecular Docking, MolecularDynamics Simulation of VEGF Inhibitors for the Clinical Treatment of Ovarian Cancer

Contact Info

Product

Resources

About